Elan shareholders approve buyback in blow to Royalty bid
DUBLIN, June 17
DUBLIN, June 17 (Reuters) - Elan shareholders approved a share buyback on Monday, meaning U.S.-based Royalty Pharma's hostile bid for the Irish drug firm will lapse unless a legal challenge it has mounted succeeds.
Royalty last month made its takeover offer conditional on shareholders rejecting four resolutions at a meeting on Monday. It won an Irish court injunction against a regulator last week, allowing it to appeal against a ruling that it cannot change the conditions attached to its offer.
Shareholders rejected Elan's proposed $1 billion royalties deal with U.S company Theravance Inc, the purchase of a private drug firm and a drug spin-off in a major blow to the company's plans. Elan put itself up for sale on Friday.
- Tweet this
- Share this
- Digg this
- Merkel asks Putin to explain reports of Russian troops in Ukraine
- Breakthrough hopes dented as Ukraine accuses Russia of new incursion |
- China urges Japan to break from aggressive past after Abe honours war criminals
- Islamic State executes soldiers, takes hostages at Syria base - social media
- Business leaders urge Scots to vote against independence